Blog  /  Insights

Physicians divided over serological data reliability

A close-up of blood samples in test tubes, capped in purple and orange, neatly arranged in a yellow rack—providing reliable serological data for physicians to analyze.

As the serological data around the globe starts to trickle in, early results reveal the actual number of Covid-19 cases could be 10 times more than the confirmed number. Sermo physicians, like the rest of the world, are conflicted over what this means and what lies ahead… 

According to a poll of more than 1,000 Sermo physicians, they are split down the middle regarding the reliability of the antibody tests—44% believe they are reliable, and 43% believe they are not reliable. Only 42% have received any serological data, while 57% are still in the dark. When comparing this pandemic to the flu, 52% believe the data proves Covid-19 is significantly more contagious than the flu; but many are waiting to see more results before deciding. 

As for the future, 77% of Sermo physicians in the poll believe a person who contracts Covid-19 will gain immunity, at least in the short term. That said, 81% fear we are still a far cry from herd immunity and returning to life as normal.

Here’s a sample of the 150+ comments on the serology topic by Sermo physicians…

A notification from General Practice (GP) about ongoing antibody tests highlights the reliability of serological data, indicating no immediate conclusions and a need for continued efforts.
The uncertainty of antibody protection is evident, with Lyme Disease highlighting a non-protective response. Physicians often rely on serological data to assess these responses, but the reliability remains questionable in predicting long-term immunity.
Text in the image: "Orthopedic Surgery: Antibody tests provide crucial serological data, but it may be hard for physicians to draw direct conclusions about the reliability of the situation across an entire population based on these ab test results.
A text discussing the differences between antibody tests for novel viruses and influenza, emphasizing the need for more serological data on virus behavior and immunity to improve their reliability and aid physicians in making informed decisions.